Pertuzumab-dpzb is now considered an interchangeable biosimilar to pertuzumab as part of treatment combinations in multiple ...
The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...
The agreement with EirGenix grants Sandoz exclusive rights to commercialize proposed biosimilar of pertuzumab for treatment ...
Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...
As Roche works to switch certain patients with breast cancer over to a fixed-dose combination of two medicines, its ...
FDA approves 1st biosimilar to Perjeta, Poherdy, for HER2-positive breast cancer treatment, enabling pharmacy-level substitution under state law.
So, I think more to come on how first line selection might evolve in the next few years depending on results from other ...
During a meeting this week, an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed 10 new ...
EirGenix inks licensing agreement with Sandoz AG for commercialization of its independently developed breast cancer biosimilar, EG1206A: Taipei Friday, November 14, 2025, 16:00 Hr ...
Digital tools can transform Africa’s healthcare outcomes – and save the continent billions - IT News Africa | Business Technology, Telecoms and Startup News ...
Poherdy can be dispensed as a substitute for Perjeta without requiring a prescription change from a health care provider.
Gilead Sciences recently announced that its Phase 3 ARTISTRY-1 trial met the primary endpoint for a novel single-tablet HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback